TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients are candidates to receive both proton beam and sorafenib~2. Patients with tumor burden that exceeds San Francisco criteria~Exclusion Criteria:~1. Patients who are candidates for surgical resection~2. Patients with tumor burden within Milan and/or San Francisco criteria~3. Patients who have contraindication to receive proton~4. Patients with contraindication to receive sorafenib including uncontrolled hypertension, coumadin treatment and prior intolerability to the drug~5. Patients treated previously by any locoregional treatment~6. Patients with prior liver transplant~7. Patients with child class C~8. Patients with model for end-stage liver disease (MELD) score of \> 25~9. Patients with other comorbid diseases that may impact survival~10. Patients with ongoing alcohol intake~11. Patients with active sepsis~12. Patients with gastrointestinal bleeding within a week~13. Patients unwilling to sign informed consent form~14. Patients with history of noncompliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Proton Beam Radiotherapy plus Sorafenib (Type: ACTIVE_COMPARATOR): A combination of radiation therapy (proton) to kill tumor cells as well as Sorafenib which is a study drug administered to patients to stop tumor growth.
- Sorafenib (Type: ACTIVE_COMPARATOR): Sorafenib is an oral pill taken daily to inhibit tumor growth at the cellular level.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Radiotherapy and Temozolomide on the Tumor Vasculature and Stem Cells in Human High-grade Astrocytomas

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed primary high-grade astrocytoma, i.e. anaplastic astrocytoma or glioblastoma multiforme.~* Have a WHO performance status 0-2 and be able to undergo outpatient treatment.~* Age ≥18 years.~* No pregnant or lactating patients can be included.~* Patients must have radiographically documented measurable disease postoperatively. At least one tumor lesion must be unidimensionally measurable as follows:~  * Tumor lesion \> 10 mm on conventional MRI scan, T1-weighted series, after intravenous (i.v.) gadolinium chelate contrast.~* All diagnostic radiology studies must be performed within 28 days prior to registration.~* Absence of conditions making MRI scans impossible;~  * Cardiac pacemaker~ * Other ferromagnetic metal implants not authorised for use in MRI such as some types of cerebral aneurysm clips~ * Serious claustrophobia~ * Obesity (\> 300 lb., 140 Kg)~* Patients who are receiving corticosteroids have to receive stable or decreasing doses for at least 14 days before entering the trial.~* No prior chemotherapy for high-grade astrocytoma~* Absence of opportunistic infections making temozolomide contraindicated.~* Minimum required laboratory data:~  * Hematology:~    * Absolute granulocytes \> 1.0 x 10\^9/L~   * Platelets \> 100 x 10\^9/L~ * Biochemistry:~    * Bilirubin \< 1.5 x upper normal limit~   * INR \< 1.5~   * Serum creatinine \<1.5 x upper normal limit~* Adequate cognitive function in order to give informed consent.~* Absence of any psychological, familial or sociological condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial~* Before patient registration/randomization, written informed consent must be given according to national and local regulations.~Exclusion Criteria:~* Lack of fulfillment of inclusion criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Non-invasive Versus Invasive Blood Pressure Measurement in the Morbidly Obese Parturient With Severe Preeclampsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written, signed and dated informed consent~* ≥ 18 years of age~* BMI \>40 kg/m2~* Has a clinically indicated radial artery line already in situ or who agree to placement of an arterial line~* Systolic blood pressure \>160 mm Hg~* Gestational age greater than or equal to 24 weeks~* Parturients admitted for induction of labor~Exclusion Criteria:~* Parturients admitted in labor

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Conical then Cylindrical (Type: EXPERIMENTAL): BP recording with noninvasive conical Ultracheck Curve BP cuff and direct invasive arterial pressure monitoring; then with traditional cylindrical BP cuff and direct invasive arterial pressure monitoring
- Arm B: Cylindrical then Conical (Type: ACTIVE_COMPARATOR): BP recording with noninvasive traditional cylindrical BP cuff and direct invasive arterial pressure monitoring; then with conical Ultracheck Curve BP cuff and direct invasive arterial pressure monitoring

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Bariatric Surgery for ESRD Patients vs Control

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Obese ESRD patients with a BMI≥ 40kg/m2 or ≥35kg/m2 with an medical complication attributed to morbid obesity (NIH guidelines).REF~2. Age ≥ 18 and ≤ 65~3. Patients must be on hemodialysis for one month.~4. Patients listed for kidney transplant in a UNOS certified kidney transplant center.~5. Patients have accrued less than 18 months of waiting time.~6. Completion of pre-RYGB psychosocial evaluation.~7. Completion of pre-RYGB dietary counseling.~8. Completion of pre-RYGB surgical risk assessment inclusive of cardiac evaluation.~9. Full reciprocal understanding of informed consent and the risks and benefits of RYGB procedure.~10. Acceptance of clinical protocol evaluations requiring scheduled clinic visits and laboratory blood draws.~Exclusion Criteria:~1. Age \< 18 and \> 65.~2. Patients with a history of peritoneal dialysis related bacterial peritonitis.~3. Peritoneal dialysis patients not willing to undergoing temporary hemodialysis.~4. History of difficult vascular access as defined by the inability to obtain permanent upper extremity or temporary jugular venous access.~5. History of poor hemodialysis performance.~6. Patients enrolled in another study within 6 months of initiation.~7. Patients listed for kidney transplant in a different UNOS region that has shorter transplant waiting times than the region governing the investigators institution.~8. Patients unwilling to be made temporarily unavailable for transplant.~9. History of non-compliance with medical care.~10. Uncontrolled psychiatric illness (ie. depression, anxiety, attention deficit disorder (ADD), uncontrolled binge eating disorder)~11. Inability to provide reciprocal understanding of informed consent.~12. Failure to complete the preoperative work-up (psychosocial, dietary and surgical risk) for RYGB.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ESRD (Type: EXPERIMENTAL): End-Stage Renal Disease (ESRD) patients on dialysis who meet the NIH guidelines and preoperative requirements for RYGB will undergo laparoscopic RYGB
- Non-ESRD (Type: ACTIVE_COMPARATOR): Non-ESRD patients who meet the NIH guidelines and preoperative requirements for RYGB will undergo laparoscopic RYGB

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Adjuntive Probiotic Therapy in Treating Urinary Tract Infections in Spinal Cord Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Spinal cord injury~* UTI~* \> 18years~* Male and females~* Prescribed antibiotics~Exclusion Criteria:~* Patients who are participating in another clinical study involving pharmaceutical products.~* Patients who are participating in other urology clinical study.~* Patients taking yogurt containing probiotic lactobacilli during the period of the study.~* Females who are pregnant and/or planning to get pregnant during the study period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Computer Stop Order Alert to Prevent Concurrent Prescribing of Trimethoprim/Sulfamethoxazole and Warfarin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~All resident physicians and nurse practitioners involved in inpatient care.~Exclusion Criteria:~None-

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- computerized alert (Type: EXPERIMENTAL): An automatic electronic stop of the tmp/sulfa or warfarin order whenever a resident or nurse practitioner places an order for tmp/sulfa with an already active warfarin order, or when ordering both simultaneously
- 2 Current practice (Type: OTHER): Current practice of the pharmacist recommending cessation of concurrent warfarin and tmp/sulfa orders

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Alveolar Management Following Teeth Extraction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Indication for tooth extraction resulting in a edentulous gap~* Male and female patients with an age range 20-60 years~* Caucasian~* For female patients: a negative pregnancy test~* Normotonic blood pressure (according to the WHO definition):~  * Men: 110/70 - 140/90 mm Hg~ * Women: 100/60- 140/90mm Hg~Exclusion Criteria:~* Parallel implantation of another implant~* Parallel planned prosthetic restoration of the adjacent teeth~* Smoker (less than 5 years non-smoker)~* Nursing women~* Participation in another clinical trial which dates back to less than 3 months before inclusion in this clinical trial~* Intake of bisphosphonates~* Radiation therapy (medical history or current)~* Known Diabetes mellitus~* Inflammatory processes in the mouth (PSI\> 2)~* Presence of autoimmune diseases (Rheumatoid arthritis, Sjögren's syndrome, Systemic lupus erythematosus)~* Presence of blood coagulation disorders (Haemophilia A/B), or the intake of anticoagulants (Warfarin, new oral anticoagulants, aspirin\> 100 mg)~* Osteogenesis imperfecta~* Osteoporosis~* Leukemia~* Agranulocytosis~* Immunocompromised patients~* Acute phase and rehabilitation phase of myocardial infarction~* Oncogenes diseases~* Patients undergoing chemotherapy~* Sepsis~* Acute and chronic infections: sinusitis, rhinitis, pharyngitis and Otitis media~* Wound healing disorders~* Seizures~* Gingival hyperplasia~* Alcohol abuse~* Drug abuse~* Infectious diseases (HIV, Hepatitis B and C)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Human-Spongiosa (IMP: drug) (Type: ACTIVE_COMPARATOR): Product Name: Human-Spongiosa,gefriergetrocknet, CHB / Pharmaceutical form: Granules / Routes of Administration: Dental use / Marketing authorisation number : 3004134.00.00 / Marketing Authorisation Holder: Institute of Transfusion Medicine, Tissue bank, Charité university of medicine Berlin / Used by socket preservation
- collacone® (IMP: medical device) (Type: ACTIVE_COMPARATOR): Product Name: Collacone / Pharmaceutical form: Absorbable, local Hemostat, porcine collagen / Routes of Administration: Dental use / Medical device with a CE mark / Used by socket preservation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Shoulder Adhesive Capsulitis and Ambulatory Continuous Interscalene Nerve Blocks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Undergoing theraputic manipulation for adhesive capsulitis of the shoulder~* age 18 years or older~* accepting a single-injection nerve block for manipulation~* understanding possible perineural infusion-related complications, study protocol, and catheter/pump care~* having caretaker through the first night after manipulation~* having an ASA physical status classification of 1-3~Exclusion Criteria:~* Any contraindications for a CISB~* any physical, mental or medical conditions which, in the opinion of the investigators, may confound quantifying postoperative pain resulting from surgery~* known allergy or other contraindication to the study medications~* pregnancy~* known hepatic or renal insufficiency/disease~* peripheral neuropathy of the surgical extremity~* morbid obesity~* inability to communicate with the investigators and hospital staff~* moderate-to-severe shoulder arthritis~* immunocompromised status of any etiology~* incarceration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1. 0.2% Ropivicaine perinueral infusion (Type: ACTIVE_COMPARATOR): Patients will receive normal standard of care post-manipulation (single-injection brachial plexus nerve block, oral analgesics, and cold therapy). They will then be randomized to 0.2% Ropivicaine attached to the perineural catheter and an infusion will be initiated. The outcome measures will be assessed by study staff on the phone and at regular visits to the surgeon's office.
- 2. Normal Saline perineural infusion (Type: PLACEBO_COMPARATOR): Patients will receive normal standard of care post-manipulation (single-injection brachial plexus nerve block, oral analgesics, and cold therapy). They will then be randomized to normal saline attached to the perineural catheter and an infusion will be initiated. The outcome measures will be assessed by study staff on the phone and at regular visits to the surgeon's office.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Dental Carotid Cognitive Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age equal to or greater than 65 years.~* Body Mass Index 18-35 kg/m2~* Mild to moderate periodontitis~* Mild to moderate cognitive impairment on Montreal Cognitive Assessment (MoCA) -range greater than or equal to 17 and less than or equal to 26 (i.e., range from 17-26).~* Detectable carotid plaque and carotid artery stenosis \<70% as diagnosed by doppler ultrasound.~* Able to perform prescribed dental hygiene and travel to medical center as required to participate in the study.~Exclusion Criteria:~* Inability to provide informed consent.~* Subjects with inability to perform cognitive and other research testing~* Prior stroke, depression (CESD \>16), neurologic or psychiatric disease that would affect cognitive testing, participation, and compliance to the research study.~* Subjects requiring chronic treatment with systemic corticosteroids or other systemic immunosuppressive drugs or drugs that would affect the dental treatments in the protocol are excluded.~* Subjects requiring essential dental care (e.g., treatment for grossly decayed teeth, broken teeth, dental abscesses, peri-apical infections, other dental infections).~* Inability to perform FDG-PET due to renal disease (eGFR \<30 mL/min/1.75m2).~* Receiving anticoagulant therapy (Warfarin) with an INR greater than 3.3 at time of dental treatment or with a bleeding disorder, or other diseases that may interfere with dental therapy.~* Subjects with medical conditions that the clinicians feel would limit their ability to participate.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Standard treatment (control) (Type: ACTIVE_COMPARATOR): Dental evaluation and dental prophylaxis at baseline, 3, 6, and 9 months and standard oral hygiene instruction.
- Intensive Treatment (Type: EXPERIMENTAL): Dental evaluation at baseline, 3, 6, and 9 months. Plus one or more sessions as needed at baseline of full mouth supra- and sub-gingival scaling and root planing, plus oral hygiene instruction. Additional sessions as necessary to remove remaining local factors and treat inflammation and bacteria overgrowth. Additional evaluations and therapy at 2 months or as needed based on therapeutic response. If bleeding on probing levels do not decrease to \<20% of sites following initial therapy or at subsequent visits, intermediate treatment visits will be scheduled. Each participant will be instructed to use half of a capful of 0.12% chlorhexidine twice a day during active treatment including two weeks beyond the treatment visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Study to Evaluate the Long-Term Safety and Efficacy of VI-0521 in Type 2 Diabetic Adults

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have completed the qualifying DM-230 trial~* If females of child-bearing potential, subjects must be using adequate contraception~* Provide written informed consent~* Be willing and able to comply with scheduled study visits, treatment plan, lab tests and other study procedures~* Be greater than 80% compliant in study medication use during the last three visits for DM-230~Exclusion Criteria:~* Subjects who have developed one or more morbidities during the DM-230 trial that would pose a safety concern

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 16-Week population (Type: EXPERIMENTAL): Placebo subjects in OB-202 (NCT00486291) and DM-230 (NCT00600067)
- 72-Week population (Type: EXPERIMENTAL): Active treatment subjects in OB-202 (NCT00486291) and DM-230 (NCT00600067)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: RCT of Progesterone to Prevent Preterm Birth in Nulliparous Women With a Short Cervix

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Nulliparous~* Cervical length as measured on transvaginal examination \< 30mm between gestational ages of 16 weeks 0 days to 22 weeks 3 days~* Gestational age 16 weeks 3 days to 22 weeks 6 days at time of randomization~Exclusion Criteria:~* Multifetal gestation~* Progesterone treatment after 14 weeks 6 days during current pregnancy~* Vaginal bleeding, heavier than spotting, after 15 weeks 6 days~* Amniotic membranes prolapsed beyond external os~* Preterm rupture of membranes~* Fetal anomaly~* Pregnancy without a viable fetus~* Current or planned cervical cerclage~* Congenital Mullerian abnormality of the uterus~* Contraindication to intra-muscular injections~* Hypertension requiring medication~* Diabetes managed with insulin or oral hypoglycemic agents~* DES exposure~* Cervical surgery such as cold knife conization~* Planned indicated preterm delivery~* Participation in another interventional study that influences age at delivery~* Participation in this trial in a previous pregnancy~* Prenatal care or delivery planned outside a MFMU Network center

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 17 alpha-hydroxyprogesterone caproate (Type: ACTIVE_COMPARATOR): 250 mg of 17 alpha-hydroxyprogesterone caproate given by weekly injection until 37 weeks gestation or delivery
- Placebo (Type: PLACEBO_COMPARATOR): Placebo oil given by weekly injection until 37 weeks gestation or delivery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy